J Kimmeyer1, T Kurzweg2, T K Hoffmann1, R Knecht2, J A Veit1, N Möckelmann2, A Münscher2, S Laban3. 1. Department of Oto-Rhino-Laryngology and Head & Neck Surgery, Head & Neck Cancer Center Ulm, University Medical Center Ulm, Frauensteige 12, 89070, Ulm, Germany. 2. Department of Oto-Rhino-Laryngology and Head & Neck Surgery, Head & Neck Cancer Center of the University Cancer Center Hamburg, University Medical Center Hamburg, Hamburg, Germany. 3. Department of Oto-Rhino-Laryngology and Head & Neck Surgery, Head & Neck Cancer Center Ulm, University Medical Center Ulm, Frauensteige 12, 89070, Ulm, Germany. simon.laban@uniklinik-ulm.de.
Abstract
BACKGROUND: The treatment of head and neck squamous cell carcinoma (HNSCC) is highly complex and requires a multimodal approach. However, guidelines for the treatment of most forms of HNSCC do not exist in German-speaking countries with the exception of oral cavity cancer. The aim of this cross-sectional study was to describe the current treatment landscape and infrastructure in German-speaking countries. METHODS: From November 2013 to July 2014, 204 departments of otorhinolaryngology (ORL) in Germany, Austria, and the German-speaking part of Switzerland were contacted and invited to take part in a web-based survey on the treatment of HNSCC. In order to cover the study in its entirety, we published three consecutive papers of which this paper is the first. RESULTS: In all, 62 treatment centers (30.4 %) participated in the survey. These centers included 21 university hospitals, 16 certified cancer centers, and 35 large centers, which diagnose at least 75 HNSCC patients annually. In 91.9 % of all cases, there were outpatient consultation hours (that were monodisciplinary in 61.4 %). A multidisciplinary tumor board was existent in 98.4 % of the cases. Of 62 ORL departments, 50 had a hospital cancer registry, 41 of 62 conducted oncological studies, and 35 of 62 assessed their patients' quality of life. CONCLUSION: The infrastructure of the treatment for HNSCC can be considered mostly well-developed and supports interdisciplinary cooperation. Potential improvements can be made regarding the standardization of tumor boards, the participation in clinical trials, and the availability of cancer registries and the data gathered therein.
BACKGROUND: The treatment of head and neck squamous cell carcinoma (HNSCC) is highly complex and requires a multimodal approach. However, guidelines for the treatment of most forms of HNSCC do not exist in German-speaking countries with the exception of oral cavity cancer. The aim of this cross-sectional study was to describe the current treatment landscape and infrastructure in German-speaking countries. METHODS: From November 2013 to July 2014, 204 departments of otorhinolaryngology (ORL) in Germany, Austria, and the German-speaking part of Switzerland were contacted and invited to take part in a web-based survey on the treatment of HNSCC. In order to cover the study in its entirety, we published three consecutive papers of which this paper is the first. RESULTS: In all, 62 treatment centers (30.4 %) participated in the survey. These centers included 21 university hospitals, 16 certified cancer centers, and 35 large centers, which diagnose at least 75 HNSCC patients annually. In 91.9 % of all cases, there were outpatient consultation hours (that were monodisciplinary in 61.4 %). A multidisciplinary tumor board was existent in 98.4 % of the cases. Of 62 ORL departments, 50 had a hospital cancer registry, 41 of 62 conducted oncological studies, and 35 of 62 assessed their patients' quality of life. CONCLUSION: The infrastructure of the treatment for HNSCC can be considered mostly well-developed and supports interdisciplinary cooperation. Potential improvements can be made regarding the standardization of tumor boards, the participation in clinical trials, and the availability of cancer registries and the data gathered therein.
Entities:
Keywords:
Germany; Guidelines; Otorhinolaryngology; Squamous cell carcinoma, head and neck; Treatment
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: Susanne Singer; Juan I Arraras; Ingo Baumann; Andreas Boehm; Wei-Chu Chie; Razvan Galalae; Johannes A Langendijk; Orlando Guntinas-Lichius; Eva Hammerlid; Monica Pinto; Ourania Nicolatou-Galitis; Claudia Schmalz; Mehmet Sen; Allen C Sherman; Karin Spiegel; Irma Verdonck-de Leeuw; Noam Yarom; Paola Zotti; Dirk Hofmeister Journal: Head Neck Date: 2012-08-21 Impact factor: 3.147
Authors: Nam P Nguyen; Paul Vos; Howard Lee; Thomas L Borok; Ulf Karlsson; Tomas Martinez; James Welsh; Deirdre Cohen; Russell Hamilton; Nga Nguyen; Ly M Nguyen; Vincent Vinh-Hung Journal: Oncology Date: 2008-10-08 Impact factor: 2.935
Authors: Felix P Kuhn; Martin Hüllner; Caecilia E Mader; Nikos Kastrinidis; Gerhard F Huber; Gustav K von Schulthess; Spyros Kollias; Patrick Veit-Haibach Journal: J Nucl Med Date: 2014-02-03 Impact factor: 10.057
Authors: Laura Evangelista; Anna Rita Cervino; Sotirios Chondrogiannis; Maria Cristina Marzola; Anna Margherita Maffione; Patrick M Colletti; Pier Carlo Muzzio; Domenico Rubello Journal: Nucl Med Commun Date: 2014-02 Impact factor: 1.690
Authors: A Psyrri; L Licitra; D Lacombe; E Schuuring; W Budach; M Ozsahin; R Knecht; J B Vermorken; J A Langendijk Journal: Ann Oncol Date: 2010-03-19 Impact factor: 32.976